Table 4. Reduction of WOMAC OA index and Lequesne index over a period of one year.
| WOMAC OA † index for the period of one year | N | change x̄ and MIN-MAX | ||
|---|---|---|---|---|
| WOMAC pain | CGS‡ | 43 | 5.29 (-5.0-16.0) | U=430.0* p<0.01 |
| NSAID§ | 36 | 2.78 (-5.0-11.0) | ||
| Total | 79 | 4.05 (-5.0-16.0) | ||
| WOMAC stiffness | CGS | 43 | 1.84 (-2.0-6.0) | U=652.0* p>0.05 |
| NSAID | 36 | 1.39 (-2.0-5.0) | ||
| Total | 79 | 1.63 (-2.0-6.0) | ||
| WOMAC function | CGS | 43 | 19.98 (0-47.0) | U=267.5* p<0.01 |
| NSAID | 36 | 6.19 (10.0-25.0) | ||
| Total | 79 | 13.7 (0-47.0) | ||
| total WOMAC score | CGS | 43 | 28.06 (14.0-67.0) | U=301.0* p<0.01 |
| NSAID | 36 | 10.17 (14.0-39.0) | ||
| Total | 79 | 19.91 (14.0-67.0) | ||
| Lequesne index before treatment after the 12th month (end of treatment) | CGS | 44 | 3.75 (-2.0-10.0) | U=652.5* p<0.05 |
| NSAID | 36 | 2.9 (-2.5-9.5) | ||
| Total | 80 | 3.37 (-2.0-10.0) | ||
*U=Mann Whitney test; †WOMAC OA Index – Western Ontario and McMaster Universities Osteoarthritis Index; ‡CGS – crystalline glucosamine sulfate; §NSAID – nonsteroidal anti-inflammatory drug